KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (ONC) Notes Payables: 2017-2025

  • BeOne Medicines' Notes Payables was N/A to $813.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $813.3 million, marking a year-over-year change of. This contributed to the annual value of $851.5 million for FY2024, which is N/A change from last year.
  • Per BeOne Medicines' latest filing, its Notes Payables stood at $813.3 million for Q3 2025, which was down 4.49% from $851.5 million recorded in Q4 2024.
  • In the past 5 years, BeOne Medicines' Notes Payables registered a high of $851.5 million during Q4 2024, and its lowest value of $813.3 million during Q3 2025.
  • Moreover, its 2-year median value for Notes Payables was $832.4 million (2024), whereas its average is $832.4 million.